Chemoembolization for primary and metastatic liver cancer

Cancer Journal

Volumn 16, Issue 2, 2010, Pages 156-162

  Liapi, Eleni ^a   Geschwind, Jean Francois H ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Drug eluting microspheres; Hepatic metastases; Hepatocellular carcinoma; Transcatheter arterial chemoembolization

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOXORUBICIN; GEMCITABINE; MICROSPHERE; MITOMYCIN C;

ANTIANGIOGENIC ACTIVITY; BILE DUCT CARCINOMA; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; HUMAN; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; OBESITY; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOMA; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS;

EID: 77951462245     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181d7e905     Document Type: Review

References (50)

1. Clouse ME, Perry L, Stuart K, et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion. 1994;55(suppl 3):92-97.
2. Roche A, Girish B, de BaÃrë T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13:136.
3. Yamada R, Nakatsuka H, Nakamura K, et al. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J. 1980;26:81-96.
4. Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148:397-401.
5. Nakakuma K, Tashiro S, Hiraoka T, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer. 1983;52:2193-2200.
6. Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol. 1983;19: 1053-1065.
7. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(5 suppl 1):S179-S188.
8. Okamura J, Kawai S, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma â€" a comparison of L-TAE with Farmorubicin and L-TAE with Adriamycin (second cooperative study). Cancer Chemother Pharmacol. 1992;31:S20.
9. Geschwind J-FH, Ramsey DE, van der Wal BCH, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol. 2003;26:111-117.
10. Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver cancer cells and endothelial cells incorporate iodised oil. Br J cancer. 1996;73:877-881.
11. Bhattacharya S, Novell JR, Winslet MC, et al. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg. 1994;81:1563-1571.
12. Terayama N, Matsui O, Gabata T, et al. Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization. Cardiovasc Intervent Radiol. 2001;24:383-387.
13. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
14. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
15. Yoshikawa M, Saisho H, Ebara M, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with lipiodol versus 4--epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol. 1994;33(suppl):S149-S152.
16. Sullivan KL. Hepatic artery chemoembolization. Semin Oncol. 2002;29:145-151.
17. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005; 104:1590-1602.
18. Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol. 2007;133: 177-184.
19. Patel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005;15:297-304.
20. Giroux MF, Baum RA, Soulen MC. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol. 2004;15:289-291.
21. Tellez C, Benson AB III, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer. 1998;82:1250-1259.
22. Geschwind J, Hong K, Georgiades C. Utility of transcatheter arterial chemoembolization for liver dominant colorectal metastatic adenocarcinoma in the salvage setting. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, January, 26-28, 2006.
23. Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005;16:353-361.
24. Reyes D, Geschwind J-FH, Wahlin T, et al. Intraarterial doxorubicin-eluting microspheres for patients with unresectable hepatocellular carcinoma: a pilot study. Athens, Greece: CIRSE; 2007:16.
25. Kamel IR, Liapi E, Reyes DK, et al. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250:466-473.
26. Hong K, Liapi E, Georgiades CS, et al. Case-controlled comparison of a percutaneous collagen arteriotomy closure device versus manual compression after liver chemoembolization. J Vasc Interv Radiol. 2005;16:339-345.
27. Geschwind J-FH, Hong K, Georgiades C. Utility of transcatheter arterial chemoembolization for liver dominant colorectal metastatic adenocarcinoma in the salvage setting. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, 2006.
28. Vogl TJ, Gruber T, Naguib NN, et al. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. AJR Am J Roentgenol. 2009;193:941-947.
29. Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009;72:517-528.
30. Liapi E, Geschwind JF, Vossen JA, et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008;190: 67-73.
31. Rajan DK, Soulen MC, Clark TW, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol. 2001;12: 187-193.
32. Vossen JA, Kamel IR, Buijs M, et al. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr. 2008;32:347-352.
33. de Luis E, Bilbao J, de Ciércoles J, et al. In vivo evaluation of a new embolic spherical particle (HepaSphere) in a kidney animal model. Cardiovascular Intervent Radiol. 2008;31:367-376.
34. Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg. 2004;139:766-774.
35. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362:1907-1917.
36. Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol. 2004;7:431-441.
37. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224-1229.
38. Livraghi T, Meloni F, Morabito A, et al. Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl. 2004;10(2 suppl 1):S98-S106.
39. Constantin M, Fundueanu G, Bortolotti F, et al. Preparation and characterisation of poly(vinyl alcohol)/cyclodextrin microspheres as matrix for inclusion and separation of drugs. Int J Pharm. 2004;285:87-96.
40. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474-481.
41. Malagari K, Chatzimichael K, Alexopoulou E, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008;31:269-280.
42. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33;41-52.
43. Reyes DK, Vossen JA, Kamel JR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009;15:526-532.
44. Saluzzo MGMC, Vignali C, Nicolini A, et al. TACE with HepaSphere microspheres loaded with chemotherapeutic agent: early experience in Italy of a multi-centre study. Washington, DC: WCIO; 2007.
45. de Baere T, Deschamps F, Teriitheau C, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol. 2008;19:855-861.
46. Aliberti C, Benea G, Tilli M, et al. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol. 2008;31:883-888.
47. Reyes DK, Vossen JA, Kamel JR, et al. Phase II trial of bevacizumab combined with transarterial chemoembolization (TACE) for hepatocellular carcinoma: initial experience at two institutions. ASCO 2010 Gastrointestinal Cancers Symposium; Orlando, FL; 2010.
48. Liapi E, Geschwind JF. Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Surg. In press.
49. Vali M, Liapi E, Kowalski J, et al. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol. 2007;18(1 pt 1):95-101.
50. Vali M, Vossen JA, Buijs M, et al. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther. 2008;327:32-37.